Dec 04, 2023 / NTS GMT
Konstantinos Biliouris - BMO Capital Markets Equity Research - Director & Biotechnology Analyst
Hello, everyone. Thanks for attending today's session. My name is Kostas Biliouris, and I am one of the biotech analysts here at BMO Capital Markets. It's a pleasure to have here with me the CEO of Ionis Pharmaceuticals, Brett Monia. And thank you, Brett. Thanks for joining us today. It's a great pleasure to have you here.
And maybe we can start with a high-level overview of the company, and then -- for those who are not familiar with Ionis, and then we can take it from there with more specific questions. Thank you.
Brett P. Monia - Ionis Pharmaceuticals, Inc. - Founder, CEO & Director
Sounds great, Kostas. Thank you for the invitation to be here today. It's a pleasure to provide an update on the great progress we're making at Ionis.
So Ionis, for those that aren't that familiar with the company, we are a well-established biotech company, now nearly 34 years old. We were created to really pioneer a new way of discovering and delivering
Ionis Pharmaceuticals Inc at BMO Capital Markets Growth & ESG Conference Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers